ClinicalTrials.gg
TerminatedNCT05232864Updated May 16, 2025Results posted

Open-label Extension Study of Efficacy, Safety and Tolerability of Secukinumab in Patients With Active Lupus Nephritis

A Phase 3 interventional study of Secukinumab in Lupus Nephritis, sponsored by Novartis Pharmaceuticals. Terminated at 18 sites in 13 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-05-16.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 3, Interventional, and Treatment

Why this study was terminated
Study terminated by sponsor based on a futility analysis of the core study CAIN457Q12301

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
31
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 10 studies in Lupus Nephritis by Novartis — 1 open to participants now, 3 under way, 2 of them phase 3. Lupus Nephritis · Novartis.

Started
2022
with 2 others
Phase 3
4 of 10
1 open now
Registered
6th of 10
by date

Among the 10 studies in Lupus Nephritis by Novartis, this one is one of 3 that started in 2022, is one of 4 in phase 3, and was the 6th registered.

Lupus Nephritis

343 studies on the registry are indexed under Lupus Nephritis; 137 are open to participants now.

Browse Lupus Nephritis studies →

Open to participants now

1 of the 10 studies in Lupus Nephritis by Novartis is open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

Who these studies take

Of the 89 Lupus Nephritis studies recruiting now, 30 (34%) set no upper age limit and 52 (58%) stop at 75 or younger; 30 take children under 18; 7 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies in Lupus Nephritis by Novartis, or all of them as a file.
02

Study summary

The purpose of this open-label extension study was to provide treatment with secukinumab for subjects who completed core study treatment in Study CAIN457Q12301 (NCT04181762), and to obtain further data on long-term efficacy, safety and tolerability of secukinunab in patients with active lupus nephritis (LN).

Read the detailed description

Investigators used their clinical judgement to decide if it might be beneficial, in terms of overall improvement and response to therapy, for subjects to enter the extension study. The planned total combined duration for the core study and this extension study was five years.

At Week 104 of the core study CAIN457Q12301, eligible subjects who completed the assessments associated with the core study visit subsequently continued in the extension study on the dose of secukinumab 300 mg administered every four weeks.

A total of 31 subjects were enrolled and received secukinumab 300 mg every four weeks until study termination. Recruitment in this study was stopped on 26-May-2023.

This study along with the core study (CAIN457Q12301) were terminated early by Novartis due to futile results of interim analysis 1 of the core study. There were no safety related reasons for early termination of either of the studies.

03

Conditions studied

  • Lupus Nephritis

Browse trials for

Keywords

  • Lupus Nephritis
  • secukinumab (AIN457)
  • estimated glomerular filtration rate
  • Urine Protein-to-Creatinine Ratio
  • Standard of Care background therapy
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key inclusion criteria:

  • Subject must have both participated in core study and completed the entire treatment period up to and including Week 104 of the core study CAIN457Q12301.
  • Subject must be deemed by the investigator to benefit from secukinumab therapy.
  • Signed must be obtained prior to participation in the study.

Key Exclusion criteria:

  • Any subject taking other concomitant biologic immunomodulating agent(s) except secukinumab.
  • Pregnant or nursing (lactating) women, where pregnancy is defined as the state of a female after conception and until the termination of gestation, confirmed by a positive human chorionic gonadotropin (hCG) laboratory test.
  • Women of , defined as all women physiologically capable of becoming pregnant, unless they are using highly effective methods of during the entire study or longer if required by locally approved prescribing information (e.g., in European Union (EU) 20 Weeks). Highly effective methods of contraception are recommended due to the known teratogenic effect of SoC (MPA).
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
31 participants (actual)

Study arms

  • Experimental
    Secukinumab

    Secukinumab 300 mg solution for subcutaneous (s.c.) injection in a 2mL Pre-Filled Syringe (PFS)

    Drug: Secukinumab

Interventions

  • 300 mg solution for subcutaneous (s.c.) injection in a 2mL Pre-Filled Syringe (PFS)

    Also known as: AIN457

06

What researchers measure

Primary outcomes

  1. Percentage of Participants Achieving Complete Renal Response (CRR)

    Complete Renal Response (CRR) is a composite endpoint defined as: * Estimated Glomerular Filtration Rate (eGFR) \>= 60 mL/min/1.73 m\^2 or no less than 85% of core Baseline values and * 24-hour Urine-to-Protein Creatinine Ratio (UPCR) =\< 0.5mg/mg The glomerular filtration rate was estimated using the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation based on subject gender, age (years) and serum creatinine (mg/dL). Central laboratory serum creatinine values were used for all renal function data analysis. UPCR was determined by a central laboratory by dividing the protein concentration by the creatinine concentration as measured in the urine collected. UPCR was determined using one of the following two types of urine collection, 24-hour urine collection or first morning void urinary sample, both of which were collected in the subjects' home.

    Time frame: Up to 28 weeks: from enrollment in the extension study (Week 104E1) up to Week 132 or Early termination of the Extension Study. Study day is defined with respect to the core study.

07

Results

Posted Aug 30, 2024

Participant flow

This study was conducted in 18 centers in 13 countries: Australia (1 site), Brazil (2 sites), Colombia (1 site), Czech Republic (2 sites), Guatemala (2 sites), Japan (2 sites), Korea (1 site), Republic of Philippines (1 site), Portugal (2 sites), Slovakia (Slovak Republic) (1 site), Spain (1 site), Thailand (1 site), Vietnam (1 site)

Participant flow — Overall Study
MilestoneSecukinumab 300 mgPlacebo to Secukinumab 300 mg
Started1615
Completed00
Not completed1615
Withdrew: Adverse event01
Withdrew: Study terminated by sponsor1614

Outcome measures

PrimaryPercentage of Participants Achieving Complete Renal Response (CRR)

Complete Renal Response (CRR) is a composite endpoint defined as: * Estimated Glomerular Filtration Rate (eGFR) \>= 60 mL/min/1.73 m\^2 or no less than 85% of core Baseline values and * 24-hour Urine-to-Protein Creatinine Ratio (UPCR) =\< 0.5mg/mg The glomerular filtration rate was estimated using the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation based on subject gender, age (years) and serum creatinine (mg/dL). Central laboratory serum creatinine values were used for all renal function data analysis. UPCR was determined by a central laboratory by dividing the protein concentration by the creatinine concentration as measured in the urine collected. UPCR was determined using one of the following two types of urine collection, 24-hour urine collection or first morning void urinary sample, both of which were collected in the subjects' home.

Time frame:
Up to 28 weeks: from enrollment in the extension study (Week 104E1) up to Week 132 or Early termination of the Extension Study. Study day is defined with respect to the core study.
Reported as:
Count of participants · Participants
Percentage of Participants Achieving Complete Renal Response (CRR)
ParticipantsSecukinumab 300 mgPlacebo to Secukinumab 300 mg
Week 104E1 (Baseline Extension Study) (n = 9, 9)45
Week 132 (n = 6, 5)35

Adverse events

Collected over On-treatment adverse events and deaths were reported from first dose of study treatment in the Core Study up to 84 days after last dose of study medication in the Extension Study, assessed up to approximately 3 year.. Non-serious events are listed at a 2% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Secukinumab 300 mg0/16 (0%)4/16 (25%)15/16 (93.8%)
Placebo to Secukinumab 300 mg0/15 (0%)8/15 (53.3%)15/15 (100%)
Most frequent serious events
Showing 10 of 13
Most frequent serious events
EventSecukinumab 300 mgPlacebo to Secukinumab 300 mg
COVID-19Infections and infestations0/162/15
Urinary tract infectionInfections and infestations0/162/15
Breast cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/162/15
DyspepsiaGastrointestinal disorders1/161/15
Drug-induced liver injuryHepatobiliary disorders0/161/15
Dengue feverInfections and infestations0/161/15
EndometritisInfections and infestations0/161/15
Pyelonephritis acuteInfections and infestations1/161/15
Bipolar disorderPsychiatric disorders0/161/15
Lupus nephritisRenal and urinary disorders0/161/15
Most frequent other events
Showing 10 of 154
Most frequent other events
EventSecukinumab 300 mgPlacebo to Secukinumab 300 mg
COVID-19Infections and infestations5/167/15
Urinary tract infectionInfections and infestations4/165/15
Herpes zosterInfections and infestations5/160/15
DiarrhoeaGastrointestinal disorders2/164/15
Upper respiratory tract infectionInfections and infestations0/164/15
AnaemiaBlood and lymphatic system disorders4/163/15
PharyngitisInfections and infestations0/163/15
HypokalaemiaMetabolism and nutrition disorders1/163/15
ArthralgiaMusculoskeletal and connective tissue disorders3/163/15
NauseaGastrointestinal disorders3/160/15

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Secukinumab 300 mgPlacebo to Secukinumab 300 mgTotal
Mean35.6 ± 8.2630.6 ± 9.8333.2 ± 9.26
Age, Customized
Age, Customized(Participants)Secukinumab 300 mgPlacebo to Secukinumab 300 mgTotal
< 30 years4711
>= 30 years12820
Sex: Female, Male
Sex: Female, Male(Participants)Secukinumab 300 mgPlacebo to Secukinumab 300 mgTotal
Female141428
Male213
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Secukinumab 300 mgPlacebo to Secukinumab 300 mgTotal
American Indian or Alaska Native606
Asian8816
Native Hawaiian or Other Pacific Islander000
Black or African American011
White268
More than one race000
Unknown or Not Reported000
08

Study locations

18 sites
  • Novartis Investigative Site
    Westmead, New South Wales 2145, Australia
  • Novartis Investigative Site
    Fortaleza, CE 60430 370, Brazil
  • Novartis Investigative Site
    Sao Paulo, SP 05403 000, Brazil
  • Novartis Investigative Site
    Barranquilla, 080020, Colombia
  • Novartis Investigative Site
    Praha 2, 128 50, Czechia
  • Novartis Investigative Site
    Praha, 12808, Czechia
  • Novartis Investigative Site
    Guatemala City, 01011, Guatemala
  • Novartis Investigative Site
    Guatemala, 01010, Guatemala
  • Novartis Investigative Site
    Kitakyushu, Fukuoka 807-8556, Japan
  • Novartis Investigative Site
    Sendai city, Miyagi 980 8574, Japan
  • Novartis Investigative Site
    Seoul, 04763, Korea, Republic of
  • Novartis Investigative Site
    Lipa City, Batangas 4217, Philippines
  • Novartis Investigative Site
    Coimbra, 3000 075, Portugal
  • Novartis Investigative Site
    Porto, 4099-001, Portugal
  • Novartis Investigative Site
    Piestany, 92101, Slovakia
  • Novartis Investigative Site
    Barcelona, Catalunya 08036, Spain
  • Novartis Investigative Site
    Bangkok, 10400, Thailand
  • Novartis Investigative Site
    Ho Chi Minh, VNM 700000, Vietnam
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Novartis is committed to sharing access to patient-level data and supporting clinical documents from eligible studies with qualified external researchers. Requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to protect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Aug 2022 to primary completion in Aug 2023, 12 months.

Results were first posted in Aug 2024, 1 year after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 31, 2022
First posted
Feb 10, 2022
StartActual
Aug 22, 2022
Primary completionActual
Aug 23, 2023
CompletionActual
Aug 23, 2023
Results first posted
Aug 30, 2024
Last update
May 16, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 16, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05232864
Responsible party
Sponsor
First posted
Feb 10, 2022
Start date
Aug 22, 2022
Primary completion
Aug 23, 2023
Completion
Aug 23, 2023
Results posted
Aug 30, 2024
Last update
May 16, 2025

Study contacts

Novartis Pharmaceuticals
study director · Novartis Pharmaceuticals

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in May 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Secukinumab

Start the discussion